Answers are grounded in this paper and cite their sources.
To analyze treatment persistence and treatment outcomes of vedolizumab as first-line biological treatment in Crohn's disease (CD) and ulcerative colitis (UC) patients in a Finnish real-world setting.
No takes yet. Share an insight, caveat, or question.
Ylisaukko‐oja et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: